share_log

Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting

Benzinga ·  May 29 20:27

Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment